News

Experts discuss how updated stroke guidelines introduce new considerations for pediatric stroke care, emphasizing improved recognition, specialized expertise, and collaboration between pediatric and adult stroke centers. [WATCH TIME: 5 minutes]

Catch up on any of the neurology headlines you may have missed in March 2026, compiled into 1 place by the NeurologyLive® team.

Nazem Atassi, MD, SVP and Global Development Head of Neurology & Gene Therapy at Novartis, discussed 64-week STEER data and the evolving role of one-time gene therapy in SMA care.

A case report of a 12-year-old boy highlighted a potential association between immunoglobulin G subclass imbalance and antibody detection in myelin oligodendrocyte glycoprotein antibody disease.

Peter Sguigna, MD, assistant professor of neurology at UT Southwestern Medical Center in Dallas, Texas, spoke on emerging research, innovative biomarkers, and expanding targeted therapies for patients living with NMOSD.

A cross-sectional study suggests excessive daytime sleepiness may represent an independent, nonmotor feature of idiopathic normal pressure hydrocephalus, separate from apnea or disease severity.

Constance V. Katsafanas, DO, director of the Neurology Residency Program at the Marcus Neuroscience Institute, highlighted the importance of individualized treatment strategies in multiple sclerosis.

Adults with Down syndrome face a high lifetime risk of early-onset Alzheimer disease linked to the triplication of chromosome 21, driving ongoing clinical investigations into targeted biomarkers and therapies for this population.

Rachele Berria, MD, PhD, Medical Affairs at Chiesi Global Rare Diseases, discussed the clinical data and implications of newly approved every-4-week dosing of pegunigalsidase alfa for Fabry disease in Europe.

The director of the Neurology Residency Program at the Marcus Neuroscience Institute detailed the importance of tailoring treatment to patients with multiple sclerosis. [WATCH TIME: 5 minutes]

A group of neuroimmunologists discuss how the updated McDonald criteria will shape neurologist training and highlight key barriers to implementation, including imaging access, resource limitations, and knowledge dissemination.

The FDA has approved a higher-dose regimen of nusinersen for spinal muscular atrophy, supported by DEVOTE data showing improved motor outcomes, reduced neurodegeneration markers, and a safety profile consistent with prior dosing.

Here's some of what is coming soon to NeurologyLive® this week.

A new obstructive sleep apnea study suggested that fatigue and objective daytime sleepiness are uncorrelated, challenging the use of the Epworth Sleepiness Scale as a measure of sleepiness.

Panelists review emerging real-world and ECTRIMS data demonstrating that the updated McDonald criteria improve earlier MS diagnosis while maintaining diagnostic accuracy across diverse clinical settings.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is GLP-1s & migraine!

Experts discuss how the updated McDonald criteria redefine radiologically isolated syndrome and explore the clinical, imaging, and access challenges of diagnosing and treating MS before symptom onset.

Neurology News Network for the week ending March 28, 2026. [WATCH TIME: 4 minutes]

Early-phase 1b trial data showed that ANX005 is generally safe and engages its complement target in Huntington disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 27, 2026.

In a preclinical study, subthalamic nucleus (STN) low-beta power negatively correlated with wake quantity, whereas STN and motor cortex high-beta power demonstrated a positive correlation with wakefulness.

A panel of MS experts breaks down the most impactful updates to the 2024 McDonald criteria, highlighting how new biomarkers, imaging features, and diagnostic flexibility are reshaping earlier and more accurate MS diagnosis.

Wolfgang Singer, MD, a professor of neurology at Mayo Clinic, spoke about the current state of biomarker research in MSA.

Purple Day, observed each March 26, highlights the global impact of epilepsy while encouraging awareness, education, and open dialogue to reduce stigma and improve care for millions worldwide.

For Purple Day, M. Scott Perry, MD, a leader within the epilepsy community, shared thoughts and perspectives on the persistent gaps in epilepsy awareness, the hope for precision therapies, and the need for holistic care.

Adult epileptologist Danielle Becker, MD, MS, FAES, emphasized the need for improved education and structured, lifespan-based care to better address sex-specific risks in women with epilepsy.

The POLARIS program includes 3 ongoing phase 1/2 clinical trials investigating the efficacy and safety of investigational gene therapy EXT101 in patients with SCN1A postive Dravet syndrome.

In honor of Purple Day®, held on March 26, 2026, Mary Anne Meskis, chief executive officer of the Dravet Syndrome Foundation, highlighted ongoing efforts and future steps to raise awareness for rare epileptic disorders.